ORIC Pharmaceuticals Reports 67% ORR in 1L Patients for Enozerinib at ESMO Asia 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Should l Buy ORIC?
Source: Newsfilter
- Clinical Trial Results: At the ESMO Asia Congress 2025, ORIC Pharmaceuticals announced that the Phase 1b trial of enozertinib achieved a 67% objective response rate (ORR) in first-line patients with EGFR exon 20 mutations, indicating strong efficacy that may surpass competitor benchmarks in treating NSCLC.
- Safety Analysis: Enozerinib demonstrated good tolerability with mostly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities, as only three patients discontinued treatment due to TRAEs, highlighting its safety profile in clinical applications.
- Performance in Brain Metastasis Patients: Among patients receiving the 80 mg dose, enozertinib achieved a 100% intracranial ORR and a 93% disease control rate (DCR), underscoring its effectiveness in patients with brain metastases and reinforcing its potential in treating complex cases.
- Future Development Plans: ORIC plans to update data in mid-2026 and advance enozertinib into Phase 3 trials, indicating the company's confidence in the drug and its potential competitiveness in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.650
Low
15.00
Averages
19.60
High
25.00
Current: 11.650
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
U.S. Stock Futures Decline as Methanex Reports Disappointing Earnings
- Earnings Miss: Methanex reported a quarterly loss of $0.14 per share, significantly below the analyst consensus estimate of $0.66 earnings per share, indicating pressure on the company amidst competitive market conditions, which may affect future investor confidence.
- Sales Shortfall: The company's quarterly sales totaled $969 million, missing the analyst consensus estimate of $1.041 billion, reflecting weak demand and market challenges that could prompt the company to adjust its strategy to navigate these conditions.
- Stock Price Plunge: Methanex shares fell sharply by 8.7% to $52.09 in pre-market trading, as investors reacted strongly to the disappointing earnings report, potentially triggering further selling pressure that could impact the company's short-term market performance.
- Market Decline: U.S. stock futures are generally lower, with Dow futures dropping around 100 points, indicating uncertainty about the economic outlook, which may influence investor risk appetite and market liquidity.
See More
ORIC Pharmaceuticals Reports Narrower Q4 Loss
- Improved Loss Metrics: ORIC Pharmaceuticals reported a narrower net loss of $30.51 million for Q4, translating to a loss of $0.30 per share, down from $36.31 million and $0.51 per share in the previous year, indicating positive financial management efforts.
- Reduced R&D Expenses: The company saw a decrease in R&D expenses to $25.86 million in Q4 from $31.97 million year-over-year, reflecting effective cost control measures that contribute to the overall reduction in operational losses.
- Widened Annual Loss: Despite the improved quarterly performance, ORIC's full-year net loss widened to $129.47 million from $127.85 million, highlighting ongoing challenges faced during the clinical development phase.
- Strong Cash Position: As of December 31, 2025, ORIC's cash, cash equivalents, and investments totaled $392.3 million, ensuring the company can continue to support its R&D projects, particularly for its clinical candidates targeting prostate cancer and non-small cell lung cancer.
See More
ORIC Pharmaceuticals Q4 2025 Financial Highlights
- Earnings Beat: ORIC Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding market expectations by $0.06, indicating potential improvement in financial performance.
- Cash Reserves Increase: As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $392.3 million, including $124.4 million from a private placement in May 2025, reflecting enhanced fundraising capabilities.
- Successful Follow-On Financing: Subsequent to Q4 2025, ORIC raised an additional $20 million in net proceeds through its ATM program, bringing total cash and investments to $412.3 million as of December 31, 2025, ensuring robust funding for future operations.
- Operational Plan Assurance: The company expects its current cash and investments to fund its operational plan into the second half of 2028, demonstrating a solid strategic positioning for R&D and market expansion.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
U.S. Stock Futures Decline as Methanex Reports Disappointing Earnings
- Earnings Miss: Methanex reported a quarterly loss of $0.14 per share, significantly below the analyst consensus estimate of $0.66 earnings per share, indicating pressure on the company amidst competitive market conditions, which may affect future investor confidence.
- Sales Shortfall: The company's quarterly sales totaled $969 million, missing the analyst consensus estimate of $1.041 billion, reflecting weak demand and market challenges that could prompt the company to adjust its strategy to navigate these conditions.
- Stock Price Plunge: Methanex shares fell sharply by 8.7% to $52.09 in pre-market trading, as investors reacted strongly to the disappointing earnings report, potentially triggering further selling pressure that could impact the company's short-term market performance.
- Market Decline: U.S. stock futures are generally lower, with Dow futures dropping around 100 points, indicating uncertainty about the economic outlook, which may influence investor risk appetite and market liquidity.
See More
ORIC Pharmaceuticals Reports Narrower Q4 Loss
- Improved Loss Metrics: ORIC Pharmaceuticals reported a narrower net loss of $30.51 million for Q4, translating to a loss of $0.30 per share, down from $36.31 million and $0.51 per share in the previous year, indicating positive financial management efforts.
- Reduced R&D Expenses: The company saw a decrease in R&D expenses to $25.86 million in Q4 from $31.97 million year-over-year, reflecting effective cost control measures that contribute to the overall reduction in operational losses.
- Widened Annual Loss: Despite the improved quarterly performance, ORIC's full-year net loss widened to $129.47 million from $127.85 million, highlighting ongoing challenges faced during the clinical development phase.
- Strong Cash Position: As of December 31, 2025, ORIC's cash, cash equivalents, and investments totaled $392.3 million, ensuring the company can continue to support its R&D projects, particularly for its clinical candidates targeting prostate cancer and non-small cell lung cancer.
See More
ORIC Pharmaceuticals Q4 2025 Financial Highlights
- Earnings Beat: ORIC Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding market expectations by $0.06, indicating potential improvement in financial performance.
- Cash Reserves Increase: As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $392.3 million, including $124.4 million from a private placement in May 2025, reflecting enhanced fundraising capabilities.
- Successful Follow-On Financing: Subsequent to Q4 2025, ORIC raised an additional $20 million in net proceeds through its ATM program, bringing total cash and investments to $412.3 million as of December 31, 2025, ensuring robust funding for future operations.
- Operational Plan Assurance: The company expects its current cash and investments to fund its operational plan into the second half of 2028, demonstrating a solid strategic positioning for R&D and market expansion.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
